Annovis Bio (NYSE:ANVS – Get Free Report) and Can-Fite BioPharma (NYSE:CANF – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.
Profitability
This table compares Annovis Bio and Can-Fite BioPharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Annovis Bio | N/A | -876.22% | -374.65% |
| Can-Fite BioPharma | -1,027.46% | -113.75% | -69.91% |
Earnings & Valuation
This table compares Annovis Bio and Can-Fite BioPharma”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Annovis Bio | N/A | N/A | -$56.20 million | ($5.75) | -1.41 |
| Can-Fite BioPharma | $667,000.00 | 10.67 | -$7.63 million | ($1.79) | -1.12 |
Institutional and Insider Ownership
15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 38.3% of Annovis Bio shares are owned by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Volatility and Risk
Annovis Bio has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings for Annovis Bio and Can-Fite BioPharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Annovis Bio | 0 | 1 | 4 | 1 | 3.00 |
| Can-Fite BioPharma | 0 | 0 | 1 | 1 | 3.50 |
Annovis Bio presently has a consensus price target of $33.60, indicating a potential upside of 315.33%. Can-Fite BioPharma has a consensus price target of $18.00, indicating a potential upside of 795.52%. Given Can-Fite BioPharma’s stronger consensus rating and higher possible upside, analysts clearly believe Can-Fite BioPharma is more favorable than Annovis Bio.
Summary
Can-Fite BioPharma beats Annovis Bio on 9 of the 13 factors compared between the two stocks.
About Annovis Bio
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
About Can-Fite BioPharma
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.
